← Eichor
Study identifier: NCT04101968 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The GBA Multimodal Study in Parkinson's Disease

Condition: Parkinson Disease · GBA Gene Mutation · Gaucher Disease  ·  Sponsor: Pacific Parkinson's Research Centre

PhaseN/A
Planned participants25
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessment to study the typing patterns as possible biomarkers of early motor dysfunctions.

This description comes directly from the study's public registry record.

Talk to the study team

Jessamyn McKenzie  ·  6048227764  ·  jess.mckenzie@ubc.ca

Always discuss trial participation with your own doctor first.

Locations (3)

Oregon Health & Science UniversityPortland, Oregon, United StatesRecruiting
University of WashingtonSeattle, Washington, United StatesRecruiting
Pacific Parkinson's Research Centre | University of British ColumbiaVancouver, British Columbia, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04101968